6-Fluoro-DET: Difference between revisions
←Created page with '{{drugbox | drug_name = 6-Fluoro-DET | image = 6-F-DET_structure.png | legal_UK = | legal_DE = | C = 14 | H = 19 | F = 1 | N = 2 | IUPAC_name = N,N-diethyl-2-(6-fluoro-1H-indol-3-yl)ethanamine | CAS_number = 2836-69-3 | CAS_number_Ref = {{cascite|correct|CAS}} | ChEMBL = | ChemSpiderID = | PubChem = 17371 | UNII = | smiles = CCN(CC)CCC1=CNC2=C1C=CC(=C2)F | StdInChI = 1S/C14H19FN2/c1-3-17(4-2)8-7-11-10-16-14-9-12(15)5-6-13(11)14...' |
(No difference)
|
Revision as of 03:31, 31 January 2022
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H19FN2 |
| Molar mass | 234.318 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-Fluoro-DET (6F-DET, 6-fluoro-N,N-diethyltryptamine) is a tryptamine derivative related to drugs such as DET and 5-Fluoro-DET. It acts as a partial agonist at the 5-HT2A receptor, but while it produces similar physiological effects to psychedelic drugs, it does not appear to produce psychedelic effects itself even at high doses. For this reason it saw some use as an "active placebo" in early clinical trials of psychedelic drugs but was regarded as having little use otherwise, though more more recent research into compounds such as AAZ-A-154 has shown that these kind of non-psychedelic 5-HT2A agonists can have various useful applications.[1][2][3][4]
See also
References
- ^ Martin W.R., Sloan J.W. (1977) Pharmacology and Classification of LSD-like Hallucinogens. In: Martin W.R. (eds) Drug Addiction II. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology (Heffter-Heubner / New Series), vol 45 / 2. Springer, Berlin, Heidelberg. doi:10.1007/978-3-642-66709-1_3
- ^ Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10. doi:10.1021/jm000339w PMID 11101361
- ^ Rabin RA, Regina M, Doat M, Winter JC. 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav. 2002 May;72(1-2):29-37. doi:10.1016/s0091-3057(01)00720-1 PMID 11900766
- ^ Nichols D.E. (2017) Chemistry and Structure–Activity Relationships of Psychedelics. In: Halberstadt A.L., Vollenweider F.X., Nichols D.E. (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin, Heidelberg. doi:10.1007/7854_2017_475
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |